Recapitulation of Ras oncogene mutations in breast cancer

Onkologie

Volumn 33, Issue 10, 2010, Pages 540-544

  Stamatakos, Michael ^a   Stefanaki, Charikleia ^a   Kontzoglou, Konstantinos ^b   Masouridi, Stavroula ^a   Sakorafas, George ^a   Safioleas, Michael ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b 2nd Department of Propaedeutic Surgery   (Greece)

Author keywords

Breast cancer; Human chromosomes; K Ras mutation; Metastasis; Oncogenesis; Pancreatic adenocarcinoma

Indexed keywords

CRK ASSOCIATED SUBSTRATE PROTEIN; CYTOPLASM PROTEIN; CYTOSKELETON PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P21; SOMATOMEDIN; SOS PROTEIN;

BREAST CANCER; CANCER CELL CULTURE; CARCINOGENESIS; GENE MUTATION; HUMAN; ONCOGENE RAS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTATION; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 77957847554     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000319697     Document Type: Review

References (38)

1. Feuer EJ, Wun LM, Boring CC, Flanders WD, Timmel MJ, Tong T: The lifetime risk of developing breast cancer. J Natl Cancer Inst 1993;85:892-897.
2. Palmer JR, Boggs DA, A dams-Campbell LL, Rosenberg L: Family history of cancer and risk of breast cancer in the Black Women's Health Study. Cancer Causes Control 2009;20:1733-1737.
3. Calaf GM, Roy D: Gene and protein expressions induced by 17beta-estradiol and parathion in cultured breast epithelial cells. Mol Med 2007;13:255-265.
4. Sinha S, Singh RK, Alam N, Roy A, Roychoud-hury S, Panda CK: Alterations in candidate genes PHF2, FANCC, PTCH1 and XPA at chromosomal 9q22.3 region: pathological significance in early-and late-onset breast carcinoma. Mol Cancer 2008;7:84.
5. Kamisawa T, Tsuruta K, Okamoto A, Horiguchi S, Hayashi Y, Yun X, Yamaguchi T, Sasaki T: Frequent and significant K-ras mutation in the pancreas, the bile duct, and the gallbladder in autoimmune pancreatitis. Pancreas 2009;38:890-895.
6. Lauchle JO, Kim D, Le DT, Akagi K, Crone M, Krisman K, Warner K, Bonifas JM, Li Q, Coakley KM, Diaz-Flores E, Gorman M, Przybranowski S, Tran M, Kogan SC, Roose JP, Copeland NG, Jenkins NA, Parada L, Wolff L, Sebolt-Leopold J, Shannon K: Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. Nature 2009;461:411-414.
7. Lee M, Ahn JH, Eum KH: The difference in biological properties between parental and v-Ha-ras transformed NIH3T3 cells. Cancer Res Treat 2009; 41:93-99.
8. Tidyman WE. Rauen KA: The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Curr Opin Genet Dev 2009;19:230-236.
9. Zhang J, Liu X, Datta A, Govindarajan K, Tam WL, Han J, George J, Wong C, Ramnarayanan K, Phua TY, Leong WY, Chan YS, Palanisamy N, Liu ET, Karuturi KM, Lim B, Miller LD: RCP is a human breast cancer-promoting gene with Ras-ac-tivating function. J Clin Invest 2009;119:2171-2183.
10. Raepple D, von Lintig F, Zemojtel T, Duchniewicz M, Jung A, Lübbert M, Boss GR, Scheele JS: Determination of Ras-GTP and Ras-GDP in patients with acute myelogenous leukemia (AML), myeloproliferative syndrome (MPS), juvenile myelomonocytic leukemia (JMML), acute lymphocytic leukemia (ALL), and malignant lymphoma: assessment of mutational and indirect activation. Ann Hematol 2009;88:319-324.
11. Zhang Y, Du G: Phosphatidic acid signaling regulation of Ras superfamily of small guanosine triphosphatases. Biochim Biophys Acta 2009; 1791:850-855.
12. Zhao X, Lu L, Pokhriyal N, Ma H, Duan L, Lin S, Jafari N, Band H, Band V: Overexpression of RhoA induces preneoplastic transformation of primary mammary epithelial cells. Cancer Res 2009;69:483-491.
13. Garron ML, Arsenieva D, Zhong J, Bloom AB, Lerner A, O'Neill GM, Arold ST: Structural insights into the association between BCAR3 and Cas family members, an atypical complex implicated in anti-oestrogen resistance. J Mol Biol 2009;386:190-203.
14. Porta M, Crous-Bou M, Wark PA, Vineis P, Real FX, Malats N, Kampman E: Cigarette smoking and K-ras mutations in pancreas, lung and colorectal adenocarcinomas: etiopathogenic similarities, differences and paradoxes. Mutat Res 2009;682:83-93.
15. Krueger F, Madeja Z, Hemberger M, McMahon M, Cook SJ, Gaunt SJ: Down-regulation of Cdx2 in colorectal carcinoma cells by the Raf-MEK-ERK 1/2 pathway. Cell Signal 2009;21:1846-1856.
16. Marusyk A, Casás-Selves M, Henry CJ, Zaberezhnyy V, Klawitter J, Christians U, DeGregori J: Irradiation alters selection for oncogenic mutations in hematopoietic progenitors. Cancer Res 2009;69:7262-7269.
17. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA: Mutations of the BRAF gene in human cancer. Nature 2002;417:949-954.
18. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmström PO, Mansukhani M, Enoksson J, Hibshoosh H, Borg A, Parsons R: PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005;65:2554-2559.
19. Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH: PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005;24:1477-1480.
20. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE: Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002;418:934.
21. McFarlin DR, Lindstrom MJ, Gould MN: Affinity with Raf is sufficient for Ras to efficiently induce rat mammary carcinomas. Carcinogenesis 2003;24: 99-105.
22. Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL: Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1987;1:1398-1402.
23. Klinakis A, Szabolc M, Chena G, Xuan S, Hibshoosh H, Efstratiadis A: Igf1r as a therapeutic target in a mouse model of basal-like breast cancer. PNAS 2009;106:2359-2364.
24. Holgado-Madruga M, Emlet DR, Moscatello DK, Godwin AK, Wong AJ: A Grb2-associated docking protein in EGF-and insulin-receptor signalling. Nature 1996;79:560-564.
25. Dankort D, Maslikowski B, Warner N, Kanno N, Kim H, Wang Z, Moran MF, Oshima RG, Cardiff RD, Muller WJ: Grb2 and Shc- adapter proteins play distinct roles in Neu (ErbB-2)-induced mammary tumorigenesis: Implications for human breast cancer. Mol Cell Biol 2001;21:1540-1551.
26. Schnelzer A, Prechtel D, Knaus U, Dehne K, Gerhard M, Graeff H, Harbeck N, Schmitt M, Lengyel E: Rac1- in human breast cancer: over-expression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene 2000;19:3013-3020.
27. Sharrocks AD: Cell cycle: sustained ERK signalling represses the inhibitors. Curr Biol 2006;16: R540-R542.
28. Murphy LO, Blenis J: MAPK signal specificity: the right place at the right time. Trends Biochem Sci 2006;31:268-275.
29. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW, Bacus SS: Cyclin E and survival in patients with breast cancer. N Engl J Med 2002;347:1566-1575.
30. Keyomarsi K, Tucker SL, Bedrosian I: Cyclin E is a more powerful predictor of breast cancer outcome than proliferation. Nat Med 2003;9:152.
31. Hunt KK, Keyomarsi K: Cyclin E as a prognostic and predictive marker in breast cancer. Semin Cancer Biol 2005;15:319-326.
32. Qiu H, Miller WT: Regulation of the nonreceptor tyrosine kinase Brk by autophosphorylation and by autoinhibition. J Biol Chem 2002;277:34634-34641.
33. Kamalati T, Jolin HE, Fry MJ, Crompton MR: Expression of the BRK tyrosine kinase in mammary epithelial cells enhances the coupling of EGF signalling to PI 3-kinase and Akt, via erbB3 phosphorylation. Oncogene 2000;19:5471-5476.
34. Qiu H, Zappacosta F, Su W, Annan RS, Miller WT: Interaction between Brk kinase and insulin receptor substrate-4. Oncogene 2005;24:5656-5664.
35. Xiang B, Chatti K, Qiu H, Lakshmi B, Krasnitz A, Hicks J, Min Yu, Miller WT, Muthuswamy SK: Brk is coamplified with ErbB2 to promote proliferation in breast cancer PNAS. 2008;105:12463-12468.
36. Malaney S, Daly RJ: The Ras signaling in mammary tumorigenesis and metastasis. J Mammary Gland Biol Neoplasia 2001;6:101-113.
37. Cohen JB, Levinson AD: A point mutation in the last intron responsible for increased expression and transforming activity of the c-Ha-ras oncogene. Nature 1988;334:119-124.
38. Youn CK, Kim MH, Cho HJ, Kim HB, Chang IY, Chung MH, You HJ: Oncogenic H-Ras up-regu-lates expression of ERCC1 to protect cells from platinum-based anticancer agents. Cancer Res 2004;64:4849-4857.